drugset / Trial / NCT00780000
Clinical Trial of Intravenous Alvespimycin in Patients With Her2 Positive Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the anti-tumor activity (via objective response rate) of alvespimycin in patients with breast cancer who have not previously received trastuzumab (except as adjuvant therapy).
Timeline
- Start
- 2008-04
- Primary completion
- 2008-06
- Completion
- 2008-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | alvespimycin | Small molecule | 80 mg/m2 | Intravenous |